Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.
(Image credit: Fred Tanneau)
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
✨ AI Summary
🔊 جاري الاستماع
تحليل ذكي | AI Editorial Analysis
•Researchers criticize betting on clinical trials for potentially promoting insider trading.
•Concerns raised about the impact of betting on the integrity of drug development.
•Kalshi and Polymarket argue that their platforms offer valuable insights for patients.
💡
لماذا يهمك هذا | Why This Matters
→Researchers criticize betting on clinical trials for potentially promoting insider trading.
→Concerns raised about the impact of betting on the integrity of drug development.
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة NPR. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by NPR. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
